Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 6, 2019
Reporting Period: Month of May 2019
This filing incorporates by reference a press release dated May 6, 2019, regarding the company's drug candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves solely to disclose a corporate development and does not contain financial statements.
Material Changes
Operational Update: Can-Fite Biopharma Ltd. announced it is conducting preparatory work for a planned pivotal Phase III study of Namodenoson.
Indication: Treatment of advanced liver cancer.
Target Population: Patients receiving first-line and second-line treatment.
Guidance, Outlook, and Risks
Outlook: The company is advancing Namodenoson into a pivotal Phase III clinical trial stage.
Forward-Looking Statements: The filing explicitly incorporates the "Forward Looking Statements" section of the attached press release into the company's Registration Statements on Form S-8 and Form F-3.
Risks: Specific risks are not detailed in the body of this filing but are referenced via the incorporated press release.
Investor Verification Checklist
- Verify the specific protocol and enrollment criteria for the planned Phase III study of Namodenoson.
- Review the full text of the press release (Exhibit 99.1) for detailed forward-looking statements and associated risk factors.
- Confirm the timeline for the initiation of the Phase III trial and expected data readout dates.
- Assess the company's current cash runway to fund the upcoming Phase III study, as this filing does not disclose liquidity figures.